BiotechTube

KHK4827-Active + KHK4827-Placebo

ApprovedWithdrawn
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Plaque Psoriasis

Conditions

Moderate to Severe Plaque Psoriasis

Trial Timeline

Jan 1, 2021 → Nov 1, 2022

NCT ID
NCT04614298

About KHK4827-Active + KHK4827-Placebo

KHK4827-Active + KHK4827-Placebo is a approved stage product being developed by Kyowa Kirin for Moderate to Severe Plaque Psoriasis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04614298. Target conditions include Moderate to Severe Plaque Psoriasis.

What happened to similar drugs?

17 of 20 similar drugs in Moderate to Severe Plaque Psoriasis were approved

Approved (17) Terminated (3) Active (3)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Risankizumab + DeucravacitinibAbbVieApproved
✅adalimumabAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04614298ApprovedWithdrawn

Competing Products

20 competing products in Moderate to Severe Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
E6007 + PlaceboEisaiPhase 2
35
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
40